Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Charcot-Marie-Tooth Disease Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Charcot-Marie-Tooth Disease Overview | 8 | 1 |
| Pipeline Products for Charcot-Marie-Tooth Disease Comparative Analysis | 9 | 1 |
| Charcot-Marie-Tooth Disease Therapeutics under Development by Companies | 10 | 1 |
| Charcot-Marie-Tooth Disease Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Charcot-Marie-Tooth Disease Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Charcot-Marie-Tooth Disease Products under Development by Companies | 14 | 1 |
| Charcot-Marie-Tooth Disease Products under Investigation by Universities/Institutes | 15 | 1 |
| Charcot-Marie-Tooth Disease Companies Involved in Therapeutics Development | 16 | 8 |
| Acetylon Pharmaceuticals, Inc. | 16 | 1 |
| Addex Therapeutics Ltd | 17 | 1 |
| Affectis Pharmaceuticals AG | 18 | 1 |
| Genzyme Corporation | 19 | 1 |
| InFlectis BioScience | 20 | 1 |
| Lead Discovery Center GmbH | 21 | 1 |
| PharmatrophiX, Inc. | 22 | 1 |
| Pharnext SAS | 23 | 1 |
| Charcot-Marie-Tooth Disease Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Combination Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 1 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 14 |
| (baclofen + naltrexone + sorbitol) Drug Profile | 33 | 2 |
| ADX-71441 Drug Profile | 35 | 3 |
| AFC-5128 Drug Profile | 38 | 1 |
| IFB-088 Drug Profile | 39 | 1 |
| LM-22B10 Drug Profile | 40 | 1 |
| Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease Drug Profile | 41 | 1 |
| Small Molecule to Inhibit Rab7 GTPase for Oncology, Neuropathy, Immunology, Neurodegenerative Diseases, Lipidoses and Charcot-Marie-Tooth Disease Type II Drug Profile | 42 | 1 |
| Small Molecules for Charcot-Marie-Tooth Disease Type I A Drug Profile | 43 | 1 |
| Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders Drug Profile | 44 | 1 |
| Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A Drug Profile | 45 | 1 |
| Stem Cell Therapy to Activate PMP22 for Charcot-Marie-Tooth Disease Type 1A Drug Profile | 46 | 1 |
| Charcot-Marie-Tooth Disease Dormant Projects | 47 | 1 |
| Charcot-Marie-Tooth Disease Product Development Milestones | 48 | 11 |
| Featured News &Press Releases | 48 | 1 |
| Apr 25, 2016: Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A | 48 | 1 |
| Feb 16, 2016: Pharnext Supports the Fight Against Rare Diseases through Development of Pleotherapy-based Treatments | 49 | 1 |
| Jan 25, 2016: IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease | 49 | 1 |
| Dec 15, 2015: Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A | 50 | 1 |
| Oct 27, 2015: FDA grants orphan drug designation to IFB-088 (Sephin1) for the treatment of Charcot-Marie-Tooth disease | 51 | 1 |
| Jun 30, 2015: Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting | 51 | 1 |
| Jan 13, 2015: InFlectis BioScience banks 1.75m to realise the potential of IFB-088 drug candidate, a breakthrough therapeutic approach to treat neurodegenerative diseases | 52 | 1 |
| Dec 17, 2014: Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A through Two Peer-Reviewed Publications | 52 | 1 |
| Oct 21, 2014: Addex And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A disorder | 53 | 1 |
| Jun 23, 2014: The EMA and FDA Grant Orphan Drug Designation to Pharnext's PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A | 54 | 1 |
| Oct 03, 2013: Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease | 55 | 1 |
| Apr 24, 2013: Addex Receives Approval To Initiate Phase I First In-man Clinical Study For ADX71441 | 55 | 1 |
| Jan 22, 2013: Addex Receives Broad US Composition Of Matter Patent For ADX71441 | 56 | 1 |
| Jan 07, 2013: Addex Therapeutics Announces Positive Data With ADX71441 In Pre-Clinical Transgenic Model Of Charcot-Marie-Tooth 1A Disease | 57 | 1 |
| Nov 22, 2011: Pharnext Completes Patient Recruitment For Phase II Study Of PXT3003 In Type 1A Charcot-Marie-Tooth Disease | 57 | 2 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |